Arcutis Biotherapeutics Inc (ARQT)

NASDAQ
20.61
-1.53(-6.91%)
After Hours
23.00
+2.39(+11.60%)
- Real-time Data
  • Volume:
    1,837,695
  • Day's Range:
    20.50 - 22.97
  • 52 wk Range:
    13.59 - 27.88

ARQT Overview

Prev. Close
22.14
Day's Range
20.5-22.97
Revenue
-
Open
22.44
52 wk Range
13.59-27.88
EPS
-4.67
Volume
1,837,695
Market Cap
1.06B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
369,063
P/E Ratio
-
Beta
-
1-Year Change
-24.75%
Shares Outstanding
51,417,963
Next Earnings Date
Aug 16, 2022
What is your sentiment on Arcutis?
or
Market is currently closed. Voting is open during market hours.

Arcutis Biotherapeutics Inc Analysis

Arcutis Biotherapeutics Inc Company Profile

Arcutis Biotherapeutics Inc Company Profile

Employees
143

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralNeutral
Technical IndicatorsStrong SellSellStrong SellSellSell
SummaryStrong SellStrong SellStrong SellNeutralNeutral